NAC is recommended for triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive cancer because these subtypes have higher rates of pathological complete response (pCR)1-5. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.